Synergistic activity of JAK2 and BCL-2 inhibition against B-cell acute lymphoblastic leukemia

被引：0
|
作者：
Rinella, Sean [1 ]
Hess, Nicholas [1 ]
Bell, Haley [1 ]
Shi, Lei [1 ]
Rui, Lixin [1 ]
Capitini, Christian [1 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22002
引用
收藏
页数：1
相关论文
共 50 条
  • [1] JAK2 Aberrations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia
    Steeghs, Elisabeth M. P.
    Jerchel, Isabel S.
    de Goffau-Nobel, Willemieke
    Hoogkamer, Alex Q.
    Boer, Judith M.
    Boeree, Aurelie
    van de Ven, Cesca
    Koudijs, Marco J.
    Besselink, Nicolle J. M.
    de Groot-Kruseman, Hester A.
    Zwaan, C. Michel
    Horstmann, Martin A.
    Pieters, Rob
    Den Boer, Monique L.
    BLOOD, 2016, 128 (22)
  • [2] JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia
    Steeghs, Elisabeth M. P.
    Jerchel, Isabel S.
    de Goffau-Nobel, Willemieke
    Hoogkamer, Alex Q.
    Boer, Judith M.
    Boeree, Aurelie
    van de Ven, Cesca
    Koudijs, Marco J.
    Besselink, Nicolle J. M.
    de Groot-Kruseman, Hester A.
    Zwaan, Christian Michel
    Horstmann, Martin A.
    Pieters, Rob
    den Boer, Monique L.
    ONCOTARGET, 2017, 8 (52): : 89923 - 89938
  • [3] JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
    Kim, Sang-Kyu
    Knight, Deborah A.
    Jones, Lisa R.
    Vervoort, Stephin
    Ng, Ashley P.
    Seymour, John F.
    Bradner, James E.
    Waibel, Michaela
    Kats, Lev
    Johnstone, Ricky W.
    GENES & DEVELOPMENT, 2018, 32 (11-12) : 849 - 864
  • [4] BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
    Korfi, K.
    Smith, M.
    Swan, J.
    Somervaille, T. C. P.
    Dhomen, N.
    Marais, R.
    CELL DEATH & DISEASE, 2016, 7 : e2177 - e2177
  • [5] BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
    K Korfi
    M Smith
    J Swan
    T C P Somervaille
    N Dhomen
    R Marais
    Cell Death & Disease, 2016, 7 : e2177 - e2177
  • [6] BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia
    Diaz-Flores, Ernesto
    Comeaux, Evan Q.
    Kim, Kailyn
    Beckman, Kyle
    Davis, Kara L.
    Wu, Kevin
    Akutagawa, Jon
    Holmfeldt, Linda
    Braun, Benjamin S.
    Mullighan, Charles
    Loh, Mignon L.
    BLOOD, 2016, 128 (22)
  • [7] B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera
    Jaitly, Vanya
    Wang, Wei
    BLOOD, 2018, 131 (08) : 941 - 941
  • [8] Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia
    Malinge, Sebastien
    Ben-Abdelali, Raouf
    Settegrana, Catherine
    Radford-Weiss, Isabelle
    Debre, Marianne
    Beldjord, Kheira
    Macintyre, Elizabeth A.
    Villeval, Jean-Luc
    Vainchenker, William
    Berger, Roland
    Bernard, Olivier A.
    Delabesse, Eric
    Penard-Lacronique, Virginie
    BLOOD, 2007, 109 (05) : 2202 - 2204
  • [9] Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
    Wu, Shuo-Chieh
    Li, Loretta S.
    Kopp, Nadja
    Montero, Joan
    Chapuy, Bjoern
    Yoda, Akinori
    Christie, Amanda L.
    Liu, Huiyun
    Christodoulou, Alexandra
    van Bodegom, Diederik
    van der Zwet, Jordy
    Layer, Jacob V.
    Tivey, Trevor
    Lane, Andrew A.
    Ryan, Jeremy A.
    Ng, Samuel Y.
    DeAngelo, Daniel J.
    Stone, Richard M.
    Steensma, David
    Wadleigh, Martha
    Harris, Marian
    Mandon, Emeline
    Ebel, Nicolas
    Andraos, Rita
    Romanet, Vincent
    Doelemeyer, Arno
    Sterker, Dario
    Zender, Michael
    Rodig, Scott J.
    Murakami, Masato
    Hofmann, Francesco
    Kuo, Frank
    Eck, Michael J.
    Silverman, Lewis B.
    Sallan, Stephen E.
    Letai, Anthony
    Baffert, Fabienne
    Vangrevelinghe, Eric
    Radimerski, Thomas
    Gaul, Christoph
    Weinstock, David M.
    CANCER CELL, 2015, 28 (01) : 29 - 41
  • [10] Fedratinib and Venetoclax Have Synergistic Activity Against B-Cell Acute Lymphoblastic Leukemia in Vitro
    Rinella, Sean P.
    Bell, Haley C.
    Shi, Lei
    Rui, Lixin
    Capitini, Christian M.
    BLOOD, 2021, 138
12345